- Home
- PPBT vs BCDA Comparison
PPBT vs BCDA Comparison
Compare PPBT & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PPBT
- BCDA
- Stock Information
- Founded
- PPBT 2010
- BCDA N/A
- Country
- PPBT Israel
- BCDA United States
- Employees
- PPBT N/A
- BCDA N/A
- Industry
- PPBT Biotechnology: Pharmaceutical Preparations
- BCDA Biotechnology: Pharmaceutical Preparations
- Sector
- PPBT Health Care
- BCDA Health Care
- Exchange
- PPBT Nasdaq
- BCDA Nasdaq
- Market Cap
- PPBT 6.2M
- BCDA 10.1M
- IPO Year
- PPBT N/A
- BCDA N/A
- Fundamental
- Price
- PPBT $2.40
- BCDA $2.39
- Analyst Decision
- PPBT Strong Buy
- BCDA Strong Buy
- Analyst Count
- PPBT 1
- BCDA 1
- Target Price
- PPBT $33.00
- BCDA $25.00
- AVG Volume (30 Days)
- PPBT 20.0K
- BCDA 230.7K
- Earning Date
- PPBT 08-15-2025
- BCDA 08-12-2025
- Dividend Yield
- PPBT N/A
- BCDA N/A
- EPS Growth
- PPBT N/A
- BCDA N/A
- EPS
- PPBT N/A
- BCDA N/A
- Revenue
- PPBT N/A
- BCDA $3,000.00
- Revenue This Year
- PPBT N/A
- BCDA N/A
- Revenue Next Year
- PPBT N/A
- BCDA N/A
- P/E Ratio
- PPBT N/A
- BCDA N/A
- Revenue Growth
- PPBT N/A
- BCDA N/A
- 52 Week Low
- PPBT $2.00
- BCDA $1.63
- 52 Week High
- PPBT $13.95
- BCDA $4.66
- Technical
- Relative Strength Index (RSI)
- PPBT 47.27
- BCDA 58.67
- Support Level
- PPBT $2.35
- BCDA $1.98
- Resistance Level
- PPBT $2.58
- BCDA $2.45
- Average True Range (ATR)
- PPBT 0.12
- BCDA 0.17
- MACD
- PPBT 0.01
- BCDA 0.04
- Stochastic Oscillator
- PPBT 43.75
- BCDA 88.00
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).